Early clinical response and presence of viral resistant minority variants: a proof of concept study.
PMID: 25397504
2014
Journal of the International AIDS Society
Abstract: Single mutations E138K (two cases) and M184V in three distinct patients and V90I+G190E; M184V+A98S; Y215F+V118I+T215I; L210S+T215I+F227L; and A62V+D67G+K70N+188H in the remaining five subjects.
Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.
Result: Some subjects harbored multiple secondary mutations (e.g., subject 905 with V90I and E138K) and/or polymorphisms (e.g., subject 237 with A98S and L101Q).The significance of the observed polymorphisms in HIV-1 non-B subtypes is unknown.
Table: V90I
Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland.
PMID: 24746180
2014
Journal of the International AIDS Society
Introduction: It must be noted, that analysis of the ECHO and THRIVE clinical data indicated that the presence of V90I, V106I, V179I and V189I was not associated with virological failure; therefore, these mutations are not likely to be associated with RPV resistance in vivo .
Introduction: Moreover, in numerous in vivo and in vitro studies, other candidate drug resistance mutations have been identified, including V90I, L100I, K101H/T, V106L, E138S,V179F/D/G/I/T, V189, G190A/E/S, F227L and M230V.|m
The case for addressing primary resistance mutations to non-nucleoside reverse transcriptase inhibitors to treat children born from mothers living with HIV in sub-Saharan Africa.
PMID: 24439027
2014
Journal of the International AIDS Society
Table: V90I
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
PMID: 24284781
2014
The Journal of antimicrobial chemotherapy
Abstract: Conversely, 11/79 (13.9%) patients randomized to etravirine had one polymorphic RAM from the etravirine score in baseline plasma (V90I, V106I or E138A), without any impact on virological outcomes.
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
PMID: 23361642
2013
The Journal of antimicrobial chemotherapy
Abstract: The common V179I, V189I and V90I polymorphisms have not been associated with virological failure in Phase 3 clinical studies.
Abstract: The other potential rilpivirine-associated mutations that were most prevalent were V179I (8.4%, n=145), V90I (3.8%, n=65) and V189I (2.3%, n=40).
Abstract: We studied the primary rilpivirine RAMs (K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C and M230I/L) and other potential rilpivirine-associated mutations (
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Abstract: In patients with ETR failure, cross-resistance to RPV was seen in 27.6%, mainly as result of Y181C (81.3%), V179I (43.8%), V90I (31.3%) and V108I (18.8%).
Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Abstract: The presence of allowed NNRTI RAMs was associated with comparable response rates to the overall population (RPV 84.3% versus EFV 82.3%, intent-to-treat time-to-loss-of-virological-response): V90I (82.4% and 100% for RPV and EFV, respectively), V106I (85.7% and 93.3%), V179I (87.7% and 94.0%) and V189I (100.0% and 88.9%).
HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection.
HIV mutation literature information.
PMID: 
2014
Journal of the International AIDS Society
Browser Board
Co-occurred Entities
Filtrator
ViMRT